Damora Therapeutics, Inc.
DMRA
$31.04
$0.311.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 22.30M | 14.80M | 9.69M | 7.32M | 8.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.35M | 64.77M | 36.56M | 11.88M | 12.57M |
| Operating Income | -96.35M | -64.77M | -36.56M | -11.88M | -12.57M |
| Income Before Tax | -262.49M | -235.00M | -209.79M | -15.85M | -16.59M |
| Income Tax Expenses | 341.00K | 90.00K | 50.00K | -2.00K | 5.00K |
| Earnings from Continuing Operations | -262.83 | -235.09 | -209.84 | -15.84 | -16.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -262.83M | -235.09M | -209.84M | -15.84M | -16.59M |
| EBIT | -96.35M | -64.77M | -36.56M | -11.88M | -12.57M |
| EBITDA | -96.33M | -64.75M | -36.54M | -11.86M | -12.55M |
| EPS Basic | -138.75 | -140.95 | -142.48 | -12.01 | -13.04 |
| Normalized Basic EPS | -13.44 | -14.75 | -15.43 | -5.38 | -6.02 |
| EPS Diluted | -138.75 | -140.95 | -142.48 | -12.01 | -13.04 |
| Normalized Diluted EPS | -13.44 | -14.75 | -15.43 | -5.38 | -6.02 |
| Average Basic Shares Outstanding | 97.71M | 37.91M | 5.45M | 5.29M | 5.10M |
| Average Diluted Shares Outstanding | 97.71M | 37.91M | 5.45M | 5.29M | 5.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |